Alle Storys
Folgen
Keine Story von Intercell AG mehr verpassen.

Intercell AG

euro adhoc: Intercell AG
other
US Defense Logistics Agency announces plans to enter into supply contract to purchase Japanese Encephalitis vaccine » Request for Proposal (RFP) aiming at exclusive, multiyear contract for Japanese Encephalitis ...

  Disclosure announcement transmitted by euro adhoc. The issuer is responsible
  for the content of this announcement.
Company Information
21.08.2008
Vienna (Austria), August 21, 2008 - Intercell AG (VSE: ICLL) 
announced that the Defense Logistics Agency (DLA), United States 
Department of Defense, has posted today a Request for Proposal (RFP) 
for purchase of Japanese Encephalitis (JE) vaccine. As JE is a 
serious and growing public health threat in Asia, the DLA intends to 
enter into a contract to purchase supplies of JE vaccine for use with
military personnel who are deployed to affected countries.
The major details of this RFP are as follows:
» Exclusive contract to supply DLA with their requirements for JE 
vaccine
» Multiyear contract, with annual options to facilitate price and 
quantity   modifications
» Duration of contract will be 5 years, at minimum
Intercell has already been in close contact with the DLA regarding 
this RFP and believes one reason for this proposed contract at this 
time is the pending Biological License Application (BLA) with the US 
Food and Drug Administration (FDA) for Intercell´s JE vaccine. 
Intercell submitted the BLA for its JE vaccine in December 2007 and 
anticipates FDA approval and subsequent first sales to the military 
markets in the next few months.
"We are pleased that the DLA has announced this RFP to establish a 
contract for supply of JE vaccine," stated Gerd Zettlmeissl, Chief 
Executive Officer of Intercell. "Intercell´s JE vaccine was developed
in collaboration with the Walter Reed Army Institute (US Department 
of Defense) and we look forward to continuing this valued 
relationship by securing a long-term, exclusive contract for supply 
of the vaccine for use in the military´s JE immunization program. 
Intercell plans to respond to this RFP in a timely manner and we are 
optimistic that we can successfully close a contract in due time."
Japanese encephalitis, a mosquito-borne flaviviral infection, remains
virulent in Asia and has recently spread to countries not previously 
infected. Hence, the virus is a constant health threat to millions of
civilian travelers and military personnel visiting or being deployed 
to affected countries, including China and India. There is no 
treatment for JE, so vaccination is the primary countermeasure 
against this disease.
end of announcement                               euro adhoc

Further inquiry note:

Intercell AG
Lucia Malfent
Head of Communications
Tel. +43 1 20620-303
lmalfent@intercell.com

Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Index: ATX Prime, ATX
Börsen: Wiener Börse AG / official market

Weitere Storys: Intercell AG
Weitere Storys: Intercell AG